Palabras clave
Enfermedades reumáticas
Autoinmunidad
Hipersensibilidad
Lupus eritematoso sistémico
Síndrome de Sjogren
Artritis reumatoide
Cómo citar
Plaudit
Resumen
Las enfermedades reumáticas autoinmunes son trastornos multisistémicos que afectan principalmente las articulaciones y los músculos; algunos ejemplos de estas afecciones son la artritis reumatoide, el lupus eritematoso sistémico y el síndrome de Sjögren. En general, las enfermedades reumáticas autoinmunes tienen una alta prevalencia en todo el mundo y son altamente incapacitantes para quienes las padecen. Una de las principales limitaciones en la actualidad para el manejo de estas enfermedades es que su factor desencadenante sigue siendo desconocido en la mayoría de los casos y el conocimiento de los factores asociados con su exacerbación es limitado. En esta revisión se explorará la posible relación de las alergias como desencadenante de enfermedades reumáticas autoinmunes. También analizaremos los aspectos básicos y generales de ambas enfermedades y el desarrollo de procesos alérgicos y reacciones de hipersensibilidad a los fármacos utilizados en el tratamiento de enfermedades reumáticas.
Referencias
Zhang L, Wu M-Q, Hao Z-L, Chiang SMV, et al. Clinical characteristics, treatments, and outcomes of patients with anti- N -methyl- d -aspartate receptor encephalitis: a systematic review of reported cases. Epilepsy Behav. 2017;68:57-65.
Dalmau J, Lancaster E, Martínez-Hernández E, Rosenfeld MR. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10(1):63-74. DOI: 10.1016/S1474-4422(10)70253-2
Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15(4):391-404. DOI: 10.1016/S1474-4422(15)00401-9
Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7(12):1091-1098. DOI: 10.1016/S1474-4422(08)70224-2
Titulaer MJ, McCracken L, Gabilondo I, Armangué T, Glaser C, Iizuka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12(2):157-165. DOI: 10.1016/S1474-4422(12)70310-1
Maneta E, Garcia G. Psychiatric manifestations of anti-NMDA receptor encephalitis: neurobiological underpinnings and differential diagnostic implications. Psychosomatics. 2014;55(1):37-44. DOI: 10.1016/j.psym.2013.06.002
Dalmau J, Graus F. Antibody-mediated encephalitis. N Engl J Med. 2018;378(9):840-851. DOI: 10.1056/NEJMra1708712
Vitaliani R, Mason W, Ances B, Zwerdling T, Jiang Z, Dalmau J. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Ann Neurol. 2005;58(4):594-604. DOI: 10.1002/ana.20614
Dalmau J, Tüzün E, Wu HY, Masjuan J, Rossi JE, Voloschin A, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61(1):25-36. DOI: 10.1002/ana.21050
Eker A, Saka E, Dalmau J, Kurne A, Bilen C, Ertoy D, et al. Testicular teratoma and anti-N-methyl-D-aspartate receptor-associated encephalitis. J Neurol Neurosurg Psychiatry. 2008;79(9):1082-1083. DOI: 10.1136/jnnp.2008.147611
Guasp M, Dalmau J. Encefalitis por anticuerpos contra el receptor de NMDA. Med Clin. 2018;151(2):71-79. DOI: 10.1016/j.medcli.2017.10.015
Granerod J, Ambrose HE, Davies NW, Clewly JP, Walsh AL, Morgan D, et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis. 2010;10(12):835-844. DOI: 10.1016/S1473-3099(10)70222-X. DOI: 10.1016/S1473-3099(10)70222-X
Gable MS, Sheriff H, Dalmau J, Tilley DH, Glaser A, et al. The Frequency of autoimmune N-Methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California encephalitis project. Clin Infect Dis. 2012;54(7):899-904. DOI: 10.1093/cid/cir1038
Huang Q, Wu Y, Qin R, Wei X, Ma M. Clinical characteristics and outcomes between children and adults with anti-N-Methyl-d-Aspartate receptor encephalitis. J Neurol. 2016;263(12):2446-2455. DOI: 10.1007/s00415-016-8282-1
Irani SR, Vincent A. NMDA receptor antibody encephalitis. Curr Neurol Neurosci Rep. 2011;11(3):298-304. DOI: 10.1007/s11910-011-0186-y
Dalmau J. NMDA receptor encephalitis and other antibody-mediated disorders of the synapse: the 2016 Cotzias Lecture. Neurology. 2016;87(23):2471-2482. DOI: 10.1212/WNL.0000000000003414
Bortnick A, Allman D. What Is and what should always have been: long-lived plasma cells induced by T cell-independent antigens. J Immunol. 2013;190(12):5913-5918. DOI: 10.4049/jimmunol.1300161
Armangue T, Moris G, Cantarín-Extremera V, Conde CE, Rostasy K, Erro ME, et al. Autoimmune post–herpes simplex encephalitis of adults and teenagers. Neurology. 2015;85(20):1736-1743. DOI: 10.1212/WNL.0000000000002125
Cull-Candy S, Brickley S, Farrant M. NMDA receptor subunits: diversity, development and disease. Curr Opin Neurobiol. 2001;11(3):327-335. DOI: 10.1016/s0959-4388(00)00215-4
Corlew R, Brasier DJ, Feldman DE, Philpot BD. Presynaptic NMDA receptors: newly appreciated roles in cortical synaptic function and plasticity. Neuroscientist. 2008;14(6):609-625. DOI: 10.1177/1073858408322675
Steffens M, Huppertz H-J, Zentner J, Chauzit E. Unchanged glutamine synthetase activity and increased NMDA receptor density in epileptic human neocortex: implications for the pathophysiology of epilepsy. Neurochem Int. 2005;47(6):379-384. DOI: 10.1016/j.neuint.2005.06.001
Olney JW, Newcomer JW, Farber NB. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res. 1999;33(6):523-533. DOI: 10.1016/S0022-3956(99)00029-1
Huang Q, Xie Y, Hu Z, Tang X. Anti-N-methyl-D-aspartate receptor encephalitis: a review of pathogenic mechanisms, treatment, prognosis. Brain Res. 2020;1727:146549. DOI: 10.1016/j.brainres.2019.146549
Hirohata S, Tanaka K. Differential expression of antibodies to NMDA receptor in anti-NMDA receptor encephalitis and in neuropsychiatric systemic lupus erythematosus. Lupus Sci Med. 2019;13;6(1):e000359. DOI: 10.1136/lupus-2019-000359
Arinuma Y. Antibodies and the brain: anti-N-methyl-D-aspartate receptor antibody and the clinical effects in patients with systemic lupus erythematosus. Curr Opin Neurol. 2018;31(3):294-299. DOI: 10.1097/WCO.0000000000000554
Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51(3):199-214. DOI: 10.1001/archpsyc.1994.03950030035004
Kayser MS, Dalmau J. Anti-NMDA receptor encephalitis, autoimmunity, and psychosis. Schizophr Res. 2016;176(1):36-40. DOI: 10.1016/j.schres.2014.10.007
Moghaddam B, Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology. 2012;37(1):4-15. DOI: 10.1038/npp.2011.181
Lynch DR, Rattelle A, Dong YN, Roslin K, Gleichman AJ, Panzer JA. Anti-NMDA receptor encephalitis: clinical features and basic mechanisms. Adv Pharmacol. 2018;82:235-260. DOI: 10.1016/bs.apha.2017.08.005
Wang R, Lai X, Liu X, Li Y-J, Chen C, Li C, et al. Brain magnetic resonance-imaging findings of anti-N-methyl-d-aspartate receptor encephalitis: a cohort follow-up study in Chinese patients. J Neurol. 2018;265(2):362-369. DOI: 10.1007/s00415-017-8707-5
Catani M, Dell’acqua F, de Schotten MT. A revised limbic system model for memory, emotion and behaviour. Neurosci Biobehav Rev. 2013;37(8):1724-1737. DOI: 10.1016/j.neubiorev.2013.07.001
Parenti A, Jardri R, Geoffroy PA. How anti-NMDAR encephalitis sheds light on the mechanisms underlying catatonia: the neural excitatory/inhibitory imbalance model. Psychosomatics. 2016;57(3):336-338. DOI: 10.1016/j.psym.2016.01.007
Finke C, Kopp UA, Pajkert A, Behrens JR, Leypoldt F, Wuerfel JT, et al. Structural hippocampal damage following anti-N-Methyl-D-aspartate receptor encephalitis. Biol Psychiatry. 2016;79(9):727-734. DOI: 10.1016/j.biopsych.2015.02.024
Dalmau J, Armangué T, Planagumà J, Radosevic M, Mannara F, Leypoldt F, et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. Lancet Neurol. 2019;18(11):1045-1057. DOI: 10.1016/S1474-4422(19)30244-3
Barry H, Hardiman O, Healy DG, Keogan M, Moroney J, Molnar PP, et al. Anti-NMDA receptor encephalitis: an important differential diagnosis in psychosis. Br J Psychiatry. 2011;199(06):508-509. DOI: 10.1192/bjp.bp.111.092197
Chapman MR, Vause HE. Anti-NMDA receptor encephalitis: diagnosis, psychiatric presentation, and treatment. Am J Psychiatry. 2011;168(3):245-251. DOI: 10.1176/appi.ajp.2010.10020181
Schieveld JNM, Strik JJMH, van Kraaij S, Nicolai J. Psychiatric manifestations and psychopharmacology of autoimmune encephalitis: a multidisciplinary approach. Handb Clin Neurol. 2019;165:285-307. DOI: 10.1016/B978-0-444-64012-3.00017-4
Gibson LL, Pollak TA, Blackman G, Thornton M, Moran N, David AS. The psychiatric phenotype of anti-NMDA receptor encephalitis. J Neuropsychiatry Clin Neurosci. 2019;31(1):70-79. DOI: 10.1176/appi.neuropsych.17120343
Liu C, Zhu J, Zheng X-Y, Ma C, Wang X. Anti-N-Methyl-D-aspartate receptor encephalitis: a severe, potentially reversible autoimmune encephalitis. Mediators Inflamm. 2017;2017:6361479. DOI: 10.1155/2017/6361479
Barry H, Byrne S, Barrett E, Murphy KC, Cotter DR. Anti-N-methyl-d-aspartate receptor encephalitis: review of clinical presentation, diagnosis and treatment. BJPsych Bull. 2015;39(1):19-23.
Maat P, de Graaff E, van Beveren NM, Hulsenboom E, Verdijk RM, Koorengevel K, et al. Psychiatric phenomena as initial manifestation of encephalitis by anti‐NMDAR antibodies. Acta Neuropsychiatr. 2013;25(3):128-136. DOI: 10.1111/acn.12013
Warren N, Siskind D, O’Gorman C. Refining the psychiatric syndrome of anti-N -methyl- d -aspartate receptor encephalitis. Acta Psychiatr Scand. 2018;138(5):401-408.
Foley SR, Kelly BD, Clarke M, McTigue O, Gervin M, Kamali M, et al. Incidence and clinical correlates of aggression and violence at presentation in patients with first episode psychosis. Schizophr Res. 2005;72(2-3):161-168. DOI: 10.1016/j.schres.2004.03.010
Compton MT, Fantes F, Wan CR, Johnson S, Walker EF. Abnormal movements in first-episode, nonaffective psychosis: dyskinesias, stereotypies, and catatonic-like signs. Psychiatry Res. 2015;226(1):192-197. DOI: 10.1016/j.psychres.2014.12.048
Waters F, Collerton D, Ffytche DH, Jardri R, Pins D, Dudley R, et al. Visual hallucinations in the psychosis spectrum and comparative information from neurodegenerative disorders and eye disease. Schizophr Bull. 2014;40(Suppl 4):S233-S245. DOI: 10.1093/schbul/sbu036
Espinola-Nadurille M, Bustamante-Gómez P, Ramírez-Bermúdez J, Bayliss L, Rivas-Alonso V, Flores-Rivera J. Frequency of neuropsychiatric disturbances in anti-NMDA receptor encephalitis. Acta Psychiatr Scand. 2018;138(5):483-485. DOI: 10.1111/acps.12963
Fink M, Taylor MA. The catatonia syndrome: forgotten but not gone. Arch Gen Psychiatry. 2009;66(11):1173-1177. DOI: 10.1001/archgenpsychiatry.2009.141
Kayser MS, Titulaer MJ, Gresa-Arribas N, Dalmau J. Frequency and characteristics of isolated psychiatric episodes in anti-N-methyl-d-aspartate receptor encephalitis. JAMA Neurol. 2013;70(9):1133.
Kataoka H, Takatani T. Psychiatric symptoms and electroencephalograms in anti-NMDAR encephalitis. Neuropsychiatry. 2018;8(1):38-41.
Reid DK, Clardy SL. Anti-NMDA-receptor encephalitis: unusual presentation of an uncommon condition. J Neurol Neurosurg Psychiatry. 2013;84(1):69-70. DOI: 10.1136/jnnp-2012-302904
Liu X, Yan B, Wang R, Li C, Chen C, Zhou D, et al. Seizure outcomes in patients with anti-NMDAR encephalitis: a follow-up study. Epilepsia. 2017;58(12):2104-2111. DOI: 10.1111/epi.13929
Viaccoz A, Desestret V, Ducray F, Picard G, Cavillon G, Rogemond V, et al. Clinical specificities of adult male patients with NMDA receptor antibodies encephalitis. Neurology. 2014;82(7):556-563. DOI: 10.1212/WNL.0000000000000126
Kleinig TJ, Thompson PD, Matar W, Duggins A, Kimber TE, Morris JG, et al. The distinctive movement disorder of ovarian teratoma-associated encephalitis. Mov Disord. 2008;23(9):1256-1261. DOI: 10.1002/mds.22073
Muñoz-Lopetegi A, Graus F, Dalmau J, Santamaria J. Sleep disorders in autoimmune encephalitis. Lancet Neurol. 2020;19(12):1010-1022. DOI: 10.1016/S1474-4422(20)30341-0
Schmitt SE, Pargeon K, Frechette ES, Hirsch LJ, Dalmau J, Friedman D. Extreme delta brush: A unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology. 2012;79(11):1094-1100. DOI: 10.1212/WNL.0b013e3182698cd8
Freund B, Ritzl EK. A review of EEG in anti-NMDA receptor encephalitis. J Neuroimmunol. 2019;332:64-68. DOI: 10.1016/j.jneuroim.2019.03.010
Yu Y, Wu Y, Cao X, Li J, Liao X, Wei J, et al. The clinical features and prognosis of anti-NMDAR encephalitis depends on blood brain barrier integrity. Mult Scler Relat Disord. 2021;47:102604. DOI: 10.1016/j.msard.2020.102604
Espinola-Nadurille M, Bautista-Gómez P, Flores J, Rivas-Alonso V, Pérez-Esparza R, Solís-Vivanco R, et al. Non-inflammatory cerebrospinal fluid delays the diagnosis and start of immunotherapy in anti-NMDAR encephalitis. Arq Neuropsiquiatr. 2018;76(1):2-5. DOI: 10.1590/0004-282X20170179
Probasco JC, Solnes L, Nalluri A, Cohen J, Jones KM, Zan E, et al. Decreased occipital lobe metabolism by FDG-PET/CT: An anti–NMDA receptor encephalitis biomarker. Neurol Neuroimmunol Neuroinflamm. 2018;5(1):e413. DOI: 10.1212/NXI.0000000000000413
Lennox BR, Coles AJ, Vincent A. Antibody-mediated encephalitis: a treatable cause of schizophrenia. Br J Psychiatry. 2012;200(2):92-94. DOI: 10.1192/bjp.bp.111.095042
Steiner J, Walter M, Glanz W, et al. Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N -Methyl-D-aspartate glutamate receptor encephalitis. JAMA Psychiatry. 2013;70(3):271.
Restrepo-Martínez M, Paola-Bautista G, Espinola-Nadurille M, Bayliss L. Banderas rojas para sospechar encefalitis anti-NMDAr en un primer episodio psicótico: reporte de dos casos. Rev Colomb Psiquiatr. 2017;48(2):127-130. DOI: 10.1016/j.rcp.2017.10.002
González-Valcárcel J, Rosenfeld MR, Dalmau J. Differential diagnosis of encephalitis due to anti-NMDA receptor antibodies. Neurologia. 2010;25(7):409-413. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3101880/
Zhang Y, Liu G, Jiang M, Chen W, Su Y. Efficacy of therapeutic plasma exchange in patients with severe refractory anti-NMDA receptor encephalitis. Neurotherapeutics. 2019;16(3):828-837. DOI: 10.1007/s13311-019-00725-4
Kuppuswamy PS, Takala CR, Sola CL. Management of psychiatric symptoms in anti-NMDAR encephalitis: a case series, literature review and future directions. Gen Hosp Psychiatry. 2014;36(4):388-391. DOI: 10.1016/j.genhosppsych.2014.02.010
Kayser MS, Dalmau J. Anti-NMDA receptor encephalitis in psychiatry. Curr Psychiatry Rev. 2011;7(3):189-193. DOI: 10.2174/157340011797183184
Lejuste F, Thomas L, Picard G, Desestret V, Ducray F, Rogemond V, et al. Neuroleptic intolerance in patients with anti-NMDAR encephalitis. Neurol Neuroimmunol Neuroinflamm. 2016;3(5):e280. DOI: 10.1212/NXI.0000000000000280
Fink M. Rediscovering catatonia: the biography of a treatable syndrome. Acta Psychiatr Scand. 2013;127(441):1-47. DOI: 10.1111/acps.12038
Warren N, Grote V, O’Gorman C, Siskind D. Electroconvulsive therapy for anti-N-methyl-d-aspartate (NMDA) receptor encephalitis: a systematic review of cases. Brain Stimul. 2019;12(2):329-334.
Santoro JD, Filippakis A, Chitnis T. Ketamine use in refractory status epilepticus associated with anti-NMDA receptor antibody encephalitis. Epilepsy Behav Rep. 2019; 23;12:100326. DOI: 10.1016/j.brs.2018.11.016
Xu X, Lu Q, Huang Y, Fan S, Zhou L, Yuan J, et al. Anti-NMDAR encephalitis: a single-center, longitudinal study in China. Neurol Neuroimmunol Neuroinflamm. 2019;16;7(1):e633. DOI: 10.1212/NXI.0000000000000633
Finke C, Kopp UA, Prüss H, Dalmau J, Wandinger KP, Ploner CJ. Cognitive deficits following anti-NMDA receptor encephalitis. J Neurol Neurosurg Psychiatry. 2012;83(2):195-198. DOI: 10.1136/jnnp-2011-300411
McKeon GL, Robinson GA, Ryan AE, Blum S, Gillis D, Finke C, et al. Cognitive outcomes following anti-N-methyl-D-aspartate receptor encephalitis: a systematic review. J Clin Exp Neuropsychol. 2018;40(3):234-252. DOI: 10.1080/13803395.2017.1329408
Gresa-Arribas N, Titulaer MJ, Torrents A, Aguilar E, McCraken L, Leypoldt F, et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol. 2014;13(2):167-177. DOI: 10.1016/S1474-4422(13)70282-5.
Wang K, Chen Z, Wu D, Ding Q, Zheng X, Wang J, et al. Early second-line therapy is associated with improved episodic memory in anti-NMDA receptor encephalitis. Ann Clin Transl Neurol. 2019;6(7):1202-1213. DOI: 10.1002/acn3.50798
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
Derechos de autor 2021 Revista Alergia México